Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Rating) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.16 and traded as high as $3.35. Oragenics shares last traded at $3.31, with a volume of 4,656 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Oragenics in a research report on Friday, April 14th. They set a "sell" rating for the company.
Get Oragenics alerts:Oragenics Stock Performance
The firm's 50 day simple moving average is $4.24 and its 200-day simple moving average is $2.16. The company has a market capitalization of $6.33 million, a price-to-earnings ratio of -24.69 and a beta of 0.19.
Hedge Funds Weigh In On Oragenics
Several institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in shares of Oragenics by 116.5% during the 2nd quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company's stock valued at $73,000 after acquiring an additional 112,800 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Oragenics by 591.6% during the 2nd quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company's stock valued at $45,000 after buying an additional 110,119 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Oragenics by 8.1% during the 1st quarter. State Street Corp now owns 495,563 shares of the biotechnology company's stock valued at $171,000 after buying an additional 37,338 shares during the last quarter. Hedge funds and other institutional investors own 9.31% of the company's stock.
Oragenics Company Profile
(Get Rating)
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
See Also
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation's Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- Why Philip Morris May Continue to Beat the Broader Market?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.